The short answer: it's shedding from weight loss, not the drug attacking your hair
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound) work by mimicking gut hormones that reduce appetite and slow stomach emptying. They do not bind receptors on hair follicles, and there is no evidence they poison or scar the follicle. What they do is enable rapid, substantial weight loss — and rapid weight loss is a well-documented trigger for a temporary shedding condition called telogen effluvium.
This distinction matters. Telogen effluvium is non-scarring and self-limiting: the follicle isn't destroyed, so hair grows back. A 2026 systematic review in Science Progress concluded that while pharmacovigilance and cohort data suggest a real association between GLP-1s (especially semaglutide and tirzepatide) and hair loss, causality has not been firmly established, and the leading proposed mechanism is the rapid weight loss itself inducing telogen effluvium — not a direct drug effect.
In other words, the hair loss you may read about on GLP-1s is the same physiologic response the body has to any big, fast systemic change — childbirth, major surgery, a severe illness, or crash dieting. That's reassuring, because those episodes almost always reverse.
What the clinical trials and FDA labels actually report
The most reliable numbers come from the pivotal randomized trials and the FDA prescribing information, not social media. For Wegovy (semaglutide 2.4 mg), the label reports alopecia in about 3.3% of patients in STEP-1 versus 1.0% on placebo over 68 weeks (Wilding, NEJM 2021; mean weight loss −14.9%). The two-year STEP-5 trial showed a nearly identical rate (~3.2% vs ~1.1%), which tells you the events happen mostly during the active weight-loss window rather than piling up indefinitely.
For Zepbound (tirzepatide 15 mg), the SURMOUNT-1 trial reported alopecia in roughly 5% of patients versus about 1% on placebo over 72 weeks — a slightly higher rate that tracks its larger mean weight loss (−20.9% at 15 mg). Notably, no trial participants discontinued Zepbound because of hair loss.
Ozempic and Mounjaro — the same molecules dosed for type 2 diabetes — do not list alopecia in their main clinical-trial adverse-event tables; hair loss appears only in the post-marketing (spontaneous-report) sections, where a rate can't be reliably calculated. The reason isn't a different drug; it's the smaller, slower weight loss at diabetes doses. This dose-and-weight-loss pattern is the single strongest clue that weight loss, not molecular toxicity, drives the shedding.
Why the risk is higher with faster, bigger weight loss (and in women)
The clearest predictor of GLP-1-associated shedding is how much and how fast you lose weight. In Wegovy data, people who lost more than 20% of their body weight had an alopecia rate of about 5.3%, versus 2.5% in those who lost less than 20%. A NIH-published study of telogen effluvium after weight loss found the condition tended to appear at a mean weight loss of roughly 15% or about 3.5 kg per month — right in the range GLP-1s can produce.
Women report the side effect several times more often than men. In pooled Wegovy data the rate was about 4% in women versus 0.9% in men; in Zepbound trials it was 7.1% in women versus 0.5% in men. This mirrors the well-established female predominance of telogen effluvium in dermatology, attributed to more frequent iron deficiency (menstrual blood loss), hormonal sensitivity of the hair cycle, and longer hairstyles that make shedding more visible.
None of this means a specific person will lose hair — the large majority in every trial did not. It means the risk clusters in strong responders losing weight quickly, which is useful context when weighing your own experience with a clinician.
How telogen effluvium works — the biology in plain terms
At any moment, roughly 85-90% of your scalp hairs are in the active growth (anagen) phase and about 10-15% are resting (telogen), according to Harvard Health. A hair grows for two to four years, rests for two to four months, then sheds and is replaced. Most people normally lose up to about 100 hairs a day.
When the body experiences a significant stressor — here, rapid weight loss and reduced calorie/protein intake — a larger-than-usual share of growing hairs is pushed prematurely into the resting phase. Because resting hairs sit in place for two to four months before falling out, you don't notice the shedding until 2-3 months after the trigger. At the peak, people may shed up to ~300 hairs a day. Researchers (Goette and Odom, and later work) attribute the mechanism specifically to caloric restriction reducing the energy supply to the rapidly dividing hair matrix, one of the highest-turnover tissues in the body.
Crucially, this is diffuse thinning across the top and sides of the scalp — not bald patches and not a receding, patterned hairline. If you see distinct bald spots or clearly patterned loss, that points to a different diagnosis and is worth a dermatologist's evaluation.
When it starts, peaks, and grows back — the typical timeline
Telogen effluvium from weight loss follows a fairly predictable arc. Shedding usually begins 2-3 months after weight loss accelerates (often when you reach the higher maintenance dose), becomes most noticeable around months 3-6, and then gradually slows. The American Academy of Dermatology puts the return to normal fullness at six to nine months after the trigger resolves. No primary study quantifies a complete-recovery percentage, so treat any “X% fully recover” figure you see as unsourced. Regrowth also lags the end of shedding by months for a mechanical reason: scalp hair grows about a centimetre a month, so density returns long after the shedding itself stops.
For GLP-1 users, most reports describe regrowth becoming visible within 3-6 months of the peak, with hair density largely restored within 6-12 months as weight stabilizes — frequently while continuing the medication. Full thickness can take up to 12-18 months because scalp hair grows slowly (about half an inch a month).
Importantly, stopping the medication is not a proven shortcut to faster regrowth, and quitting can trigger weight regain — itself another systemic stressor. Any decision to change or stop a medication should be made with the prescribing clinician, not based on shedding alone.
What may help reduce shedding: protein, nutrients, and a gradual pace
Because the trigger is rapid weight loss and under-nutrition, the evidence-based levers focus on nutrition and pace — not on the drug's mechanism. Cleveland Clinic's telogen effluvium guidance recommends eating extra protein (about 40-60 grams a day at minimum, and more if you're vegetarian or vegan), since low protein intake and crash-style calorie restriction are documented TE triggers. GLP-1 medications blunt appetite, so hitting a protein target takes deliberate effort — this is a common reason clinicians and registered dietitians emphasize protein-forward meals for people on these drugs.
Iron matters too. Dermatology references note that low ferritin (a marker of iron stores) is commonly checked in people with diffuse shedding, and correcting a documented deficiency can support regrowth. That said, the evidence does not support iron or other supplements for people who are not actually deficient — routine iron supplementation without deficiency is not recommended, and blood testing is the way to know. A clinician can order ferritin, iron studies, thyroid tests, and a complete blood count to rule out contributors.
A gentler pace of weight loss may lower the odds of a pronounced shedding episode, since risk tracks the speed and magnitude of loss. Whether and how to adjust titration is a clinical decision — this page can't and won't tell you to change a dose.
- Prioritize protein at every meal (Cleveland Clinic: ~40-60 g/day minimum; more for larger bodies or plant-based diets — confirm your target with a clinician or dietitian).
- Eat iron- and zinc-rich foods (eggs, fish, poultry, legumes, seeds, spinach); treat a lab-confirmed deficiency rather than guessing.
- Don't crash-diet on top of the medication — very-low-calorie intake is an independent TE trigger.
- Be skeptical of 'hair growth' supplements: biotin and similar products are not FDA-evaluated for efficacy and have no proven benefit for telogen effluvium unless you're deficient.
- Ask your clinician before adding any supplement, and about labs (ferritin, iron, TSH, CBC) if shedding is significant.
When to see a dermatologist
Most weight-loss-related shedding resolves on its own, but a dermatologist should evaluate hair loss that doesn't fit the telogen effluvium pattern or doesn't recover. Telogen effluvium is diffuse and non-scarring; distinct bald patches, patchy circular loss, or a clearly patterned hairline are red flags for other conditions (such as alopecia areata or androgenetic/pattern hair loss, which rapid weight loss can 'unmask').
Reasonable reasons to seek a dermatologist or your clinician: shedding that is severe or accelerating, no visible regrowth after roughly 12 months, a family history of pattern baldness alongside patterned thinning, scalp redness/itch/scaling, or shedding paired with symptoms of thyroid disease or anemia. A dermatologist can perform a pull test, review your history and medications, and order targeted labs.
Pattern (androgenetic) hair loss will not simply reverse on its own the way telogen effluvium does — it has its own treatments (for example, topical minoxidil), which a clinician can discuss. Getting the right diagnosis before trying to treat it is the single most important step.
A note on compounded GLP-1s and 'natural' alternatives
Compounded semaglutide and tirzepatide are not FDA-approved finished drugs; they are prepared by compounding pharmacies and have not gone through the same finished-product review or the clinical trials that generated the hair-loss data above. Because they deliver the same active molecules and can drive the same rapid weight loss, the telogen-effluvium mechanism would plausibly apply — but the exact rates, quality, and dosing are not established the way they are for brand products. If you use a compounded version, that uncertainty is worth discussing with a licensed provider.
Supplements marketed as 'natural Ozempic' — berberine, and various fibers or herbal blends — are not FDA-approved to treat obesity and are not equivalent to prescription GLP-1s. The FDA does not evaluate dietary supplements for efficacy before they're sold. They should not be treated as a substitute for a prescribed medication, and there's no reliable evidence that swapping to a supplement prevents or treats hair loss.